Please login to the form below

Not currently logged in

Kiadis Pharma appoints Vincent Brichard to supervisory board

Dr Brichard has over 25 years of experience in oncology and immunology

edit-Kiadis-Vincent-BrichardClinical stage biopharma firm Kiadis Pharma has named Dr Vincent Brichard as an independent member of its supervisory board.

Kiadis has a focus on research, development and commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders, including its lead product Atir.

Commenting on his appointment, Brichard said: “With my background in oncology and immunology, my work has been focused since 1986 on the appealing project of educating our natural defenses – those that protect us from infectious diseases – to recognise and kill cancer cells. 

“Atir achieved some extremely compelling clinical data and the phase II study interim analysis in December demonstrated the drug's true potential as an adjunctive life-saving therapy for blood cancer patients. I am looking forward to joining the board and working with the team to develop Atir to its full potential.

Brichard has more than 25 years of experience in the fields of oncology and immunology, including an almost 15 year stint as GlaxoSmithKline where he served as senior VP and held responsibility for the immunotherapies business unit.

Manfred Rüdiger, CEO of Kiadis, added: “We are very pleased to have attracted someone of Dr Brichard's calibre to the board. His strong background and successful career in oncology and immunology will complement the company's already strong team and network. We look forward to benefiting from his counsel.”

20th May 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge